Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / EVER Pharma - LARVOL DELTA

Improvement of aphasia deficits following traumatic intracranial hemorrhage: a case report. (PubMed, J Med Life) - "Spontaneous subacute recovery and the concurrent speech-language therapy may account for the change, and a single patient cannot establish an effect; the time course and the size of the change nonetheless raise the possibility of an adjunctive neurorestorative contribution from Cerebrolysin in post-traumatic hemorrhagic aphasia. Controlled studies in TBI populations are needed."

Journal • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Vascular Neurology

An Adaptive, Time-Informed, Phenotype-Guided Pharmacological Framework for Severe Traumatic Brain Injury : A Hypothesis-Driven Narrative Review. (PubMed, J Korean Neurosurg Soc) - "Glibenclamide/glyburide and hypertonic sodium lactate produced preliminary imaging or physiological signals without demonstrated functional benefit. Riluzole was neutral in an adult randomized trial, whereas a small study in chronic TBI found that minocycline reduced a neuroinflammatory imaging signal but increased plasma neurofilament light. Metformin and N-acetylcysteine plus probenecid provided exploratory pharmacokinetic, biomarker, or safety data. Amantadine provided phenotype-specific clinical proof of principle in traumatic disorders of consciousness. Cerebrolysin showed mixed human evidence, including a favorable day-90 multidimensional ensemble signal that requires independent replication. Deferoxamine and clemastine remain preclinical...Module activation should require optimized foundational care, a matching phenotype, measurable target activation or engagement, and acceptable systemic safety. This framework prioritizes phenotype-enriched, single-module..."

Journal • CNS Disorders • Vascular Neurology • Plasma NfL

Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report. (PubMed, Case Rep Neurol Med) - "This report is not intended to establish the therapeutic efficacy of short-course adjunctive cerebrolysin. It illustrates how clinical signals from randomized and observational studies can be interpreted for the purpose of individual therapeutic decisions."

Journal • Cardiovascular • Hematological Disorders • Reperfusion Injury

Post-Endovascular Thrombectomy Perfusion Imaging (CT and MR) as a Prognostic Biomarker and Patient-Selection Tool for Adjuvant Therapy: A Systematic Review, Meta-Analysis, and Clinical Threshold Framework. (PubMed, J Stroke Cerebrovasc Dis) - "Post-EVT perfusion imaging (CT or MR) provides tissue-level reperfusion information that complements modified Thrombolysis in Cerebral Infarction (mTICI) grading and identifies biologically distinct patient subgroups. Standardized post-EVT perfusion imaging at 30-120 minutes, applied with the proposed threshold framework, should be considered as an eligibility criterion and stratification variable in future trials of post-EVT adjuvant therapy across the pharmacological spectrum."

Biomarker • Journal • Retrospective data • Cardiovascular • CNS Disorders • Ischemic stroke

Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report. (PubMed, J Med Life) - "Early multidisciplinary rehabilitation, combined with a 10-day course of Cerebrolysin, memantine, and sertraline, was associated with substantial improvements in language, motor function, and independence over a three-month period. This case highlights the potential synergistic effect of Cerebrolysin in a young patient with early reperfusion and intensive rehabilitation, including pharmacotherapy and SLT, especially in settings where optimal post-stroke rehabilitation resources may be limited."

Journal • Cardiovascular • Ischemic stroke

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report. (PubMed, J Med Life) - "Successful reperfusion remains the key determinant of outcome in BAO, and no causal inference can be made regarding Cerebrolysin. This case adds to the limited evidence on the use of Cerebrolysin as an adjunct to reperfusion therapy and supports further investigation in controlled studies of posterior circulation stroke."

Journal • Cardiovascular • CNS Disorders

Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Chang Gung Memorial Hospital | Phase classification: P1 ➔ P2 | Trial completion date: Jul 2027 ➔ Dec 2030 | Trial primary completion date: Dec 2026 ➔ Dec 2029

Phase classification • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Research-Evidence-Practice Gaps in Post-stroke Neuro-recovery Pharmacological Therapies in Asia. (PubMed, Cerebrovasc Dis Extra) - "We found research-evidence-practice gaps in several post-stroke treatments for neuro-recovery, particularly in terms of availability and inclusion in clinical guidelines. Bridging the gap between research and practice will be crucial to improve patient outcome."

Journal • Cardiovascular • CNS Disorders • Depression • Psychiatry

Predictors of Psychoactive and Nootropic Substance Use Among Romanian University Healthcare Students: The Interplay Between Academic Anxiety and Educational Advancement. (PubMed, Healthcare (Basel)) - "It has been demonstrated that the probability of using synthetic nootropics (piracetam/cerebrolysin) increases by 1.86 times (OR = 1.86, p = 0.021) as university education progresses (nN= 335). The findings of this study highlight that many university students in the healthcare field use cognitive stimulants during periods of intellectual overload, with more than 40% of participants utilizing CEs daily or weekly in periods of academic stress. Overload schedule, academic stress, the knowledge about their positive effects, and psychosocial contexts influence consumption."

Journal • Cardiovascular • Fatigue • Mood Disorders • Psychiatry

Synergistic Effects of Cerebrolysin and Aerobic Exercise on 6-hydroxydopamine-induced Model of Parkinson Disease in Adult Male Rats. (PubMed, Basic Clin Neurosci) - "Notably, the combination effects were greater than single therapy and levodopa treatment. Our findings indicate that the combination of exercise and CBL ameliorated 6-OHDA-induced motor impairments by attenuating oxidative stress and protein expression of α-synuclein and preserving neurons in the SN."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability. (PubMed, Cells) - "Treatment of fibrin- and tPA-challenged CECs with Cerebro-Exos robustly reduced fibrin- and tPA-augmented proteins involved in inflammation and coagulation and substantially increased fibrin- and tPA-decreased proteins that are related to tight junctions and metabolism. Collectively, these data indicate that Cerebro-Exos have a broad effect on improvement of dysfunctional CECs, which is likely achieved by the alteration of CEC proteins."

Journal • Inflammation

Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles. (PubMed, Neurochem Res) - No abstract available

Journal • Neuralgia • Pain

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis. (PubMed, Asian J Neurosurg) - "While Cerebrolysin showed promising effects, the nonrandomized and single-blind design limits causal inference. Further randomized controlled trials are warranted."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders • Vascular Neurology

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness (clinicaltrials.gov) - P4 | N=12 | Recruiting | Sponsor: Konkuk University Medical Center | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Sep 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the Helix pomatia-Snail Model of Learning and Memory. (PubMed, Biomolecules) - "In this study, we examined the impact of L-kynurenine (a KYNA substrate) and the anti-dementia drugs D-cycloserine and Cerebrolysin on kynurenine aminotransferase (KAT) activity, an enzyme forming KYNA, in liver homogenates of Helix pomatia snails...A drug or natural extract that blocks KYNA synthesis has the ability to increase tentacle lowering and could be considered an anti-dementia agent. Furthermore, this metabolite may also protect against aging and delay damage to the central nervous system related to memory."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • Psychiatry

Therapy prospects for post-stroke aphasia (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Cerebrolysin, a pleiotropic drug composed of peptides with neurotrophic properties and free amino acids, can activate neuroplasticity. Recent findings from the Efficacy and Safety of Cerebrolysin in the Treatment of Aphasia After Acute Ischemic Stroke study (ESCAS) demonstrate that combined speech therapy and Cerebrolysin use accelerates recovery of speech functions, suggesting its value as an adjunct in stroke rehabilitation."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Ischemic stroke

The Efficacy and Safety of Cerebrolysin on Functional Outcomes in Acute Ischemic Stroke: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Conclusions Cerebrolysin demonstrates potential benefits in reducing NIHSS scores, improving ARAT and BI as continuous outcomes, and enhancing upper limb FMA in later phases, with favorable trends in mRS and MMSE, though heterogeneity and non-significant effects in some dichotomous outcomes limit conclusions. Safety profiles were comparable to placebo, supporting its use as an adjunct in stroke rehabilitation."

Retrospective data • Review • Cardiovascular • Ischemic stroke

Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice. (PubMed, J Alzheimers Dis) - No abstract available

Journal • Preclinical

Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease. (PubMed, Mol Neurobiol) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed, Brain Behav) - "Cerebrolysin shows promise as a useful neuroprotective treatment in stroke care by dramatically improving functional recovery, reducing symptomatic intracranial bleeding, and lowering mortality in acute ischemic stroke patients when used in conjunction with mechanical thrombectomy. Nonetheless, these conclusions are derived from only three observational studies with small sample sizes, which limits the robustness and generalizability of the findings. Further large-scale randomized trials are warranted to confirm these effects."

Clinical • Journal • Observational data • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome. (PubMed, Acta Neuropathol) - No abstract available

Journal • Developmental Disorders • Movement Disorders

The Role of Cerebrolysin in Promoting Axonal Regeneration and Functional Recovery after Peripheral Nerve Injury: A Focus on Macrophage Activation. (PubMed, Adv Pharm Bull) - "The 5 mg/kg dosage proved to be more effective than the 2.5 mg/kg dose. This study highlights the potential of Cerebrolysin as a therapeutic agent for peripheral nerve injuries."

Journal • Muscular Atrophy

The effect of Cerebrolysin on the development of skills in patients after acute cerebrovascular accidents (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The use of Cerebrolysin in a dose of 10 ml to 30 ml during post-stroke rehabilitation leads to an increase in the quantity and quality of restored functions and formed skills, which was shown in a small group of 10 studies."

Journal • Review • Cardiovascular • CNS Disorders • Depression • Psychiatry

The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Thus, when administered at the onset of reperfusion following MCA occlusion, Mexidol exerts the most pronounced cerebroprotective effect, stimulating neurogenesis and suppressing the development of neuroinflammation and apoptosis."

Journal • Cardiovascular • Oncology • BAX • BDNF • CASP3 • TNFA

Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies. (PubMed, J Clin Neurol) - No abstract available

Journal • Retrospective data • Hematological Disorders